Corvus Pharmaceuticals, Inc.

CRVS

US2210151005

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:45:29 2024-07-16 EDT			5-day change	1st Jan Change
2.17 ^USD	+8.50%		+19.89%	+23.30%

07-12	GoodRx Holdings, Inc. Announces the Election of Ian T. Clark to its Board of Directors	CI
07-01	Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) dropped from Russell Microcap Value Index	CI

Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) dropped from Russell Microcap Value Index

July 30, 2024

Latest news about Corvus Pharmaceuticals, Inc.

GoodRx Holdings, Inc. Announces the Election of Ian T. Clark to its Board of Directors	07-11	CI
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) dropped from Russell Microcap Value Index	06-30	CI
Corvus Pharmaceuticals, Inc.(NasdaqGM:CRVS) dropped from Russell 3000E Value Index	06-30	CI
Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing	05-07	MT
Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating	05-07	MT
Transcript : Corvus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 06, 2024	05-06
Corvus Pharmaceuticals, Inc. Provides Business Update	05-06	CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	04-30	MT
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	04-09	CI
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	03-20	MT
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	03-19	MT
Transcript : Corvus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 19, 2024	03-19
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-19	CI
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	02-12	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	02-09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	02-09	MT
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	02-09	MT
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	02-08	DJ
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	02-06	CI
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	01-23	CI
Corvus Pharmaceuticals, Inc. Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial	12-09	CI
Transcript : Corvus Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI

Chart Corvus Pharmaceuticals, Inc.

Duration

Period

More charts

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumorâs ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Companyâs third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2 USD

Average target price

7.833 USD

Spread / Average Target

+291.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CORVUS PHARMACEUTICALS, INC.	+23.30%	125M
MODERNA, INC.	+25.14%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.27%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.00%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.95%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.97%	14.52B
MEDPACE HOLDINGS, INC.	+47.52%	13.74B
BIO-TECHNE CORPORATION	+3.28%	12.17B

Other Biotechnology & Medical Research